JaishriO'neillBlakeleyMD

Neurooncology

Professor of Neurology, Professor of Neurological Surgery, Professor of Oncology, Johns Hopkins University School of Medicine; Director, The Johns Hopkins Comprehensive Neurofibromatosis Center; Director, neurofibromatosis therapeutic acceleration program

Join to view full profile

Dr. Blakeley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Blakeley's full profile

Already have an account?

Office
601 North Caroline Street
Baltimore, MD 21287
Phone+1 410-955-9441

Fax+1 410-955-6402

Summary

Dr. Jaishri Blakeley is a neurologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. She received her medical degree from Baylor College of Medicine and has been in practice 16 years. She specializes in neurooncology and is experienced in neurofibromatosis, neuro-oncology, gliomas, drug delivery systems, and clinical trials.

Education & Training

Johns Hopkins UniversityResidency, Neurology, 2002 - 2005
Baylor College of MedicineInternship, Internal Medicine, 2001 - 2002
Baylor College of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2023 - Present
MD State Medical License 2006 - 2026
NC State Medical License 2020 - 2022
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma Start of enrollment: 2008 Jan 01
Terminated
Not Applicable
Concentration and Activity of Lapatinib in Vestibular Schwannomas Start of enrollment: 2009 Jun 01
Completed
Early Phase 1
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Jul 01
Completed
Phase 2
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Start of enrollment: 2010 Oct 01
Completed
Phase 2
Low Dose Radiation Therapy for Glioblastoma Multiforme Start of enrollment: 2012 Sep 01
Completed
Phase 2
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Start of enrollment: 2013 May 15
Completed
Phase 2
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Start of enrollment: 2014 Jun 01
Completed
Phase 2
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Start of enrollment: 2014 Jun 01
Completed
Phase 2
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Start of enrollment: 2020 Jun 20
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor Start of enrollment: 2021 Jun 08
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

307 citations
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.
Eric Legius, Ludwine Messiaen, Pierre Wolkenstein, P Pancza, Robert A. Avery
Genetics in Medicine. 2021-05-19
19 citations
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
Andrea M Gross, Eva Dombi, Pamela L Wolters, Andrea Baldwin, Anne Dufek
Neuro-Oncology. 2023-10-03
75 citations
The Diagnosis and Management of Neurofibromatosis Type 1
K. Ina Ly, Jaishri O. Blakeley
The Medical Clinics of North America. 2019-11-01

Lectures

Familial Unilateral Vestibular Schwannoma Is Rarely Caused by Inherited Variants in the NF2 Gene
ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019

Press Mentions

Bringing Brigatinib to Neurofibromatosis Type-2 Patients: From Promising Potential to Platform Clinical TrialMay 29th, 2020
Health Beat: NF Tumors: Hearing Can Be RestoredSeptember 21st, 2016
Anticancer Drug Restores Hearing in Some Patients with NeurofibromatosisMarch 14th, 2016